【帕金森】Neuron23完成9,650萬美元D輪，並完成NEU-411治療早期PD二期臨床首例給藥

 【帕金森】《Neuron23》完成9,650萬美元D輪融資，並完成NEU-411治療早期帕金森氏症(LRRK2)的全球二期臨床試驗首例患者給藥

 文章出處  

Neuron23 

 

 原文標題  

Neuron23 Announces $96.5 Million Series D Financing and First Patient Dosed in Global Phase 2 NEULARK Clinical Trial of NEU-411 for Early Parkinson’s Disease 

 

 Twitter  

https://x.com/aimedadviser/status/1937687439579206020 

 

 文章序號  

8345 

 

智醫科學－AI醫療技術、應用與市場動態

Copyright ©2025 智醫科學 MEDai.tw All rights reserved.

The content of this site is intended for healthcare and medical professionals.